Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

BACKGROUND: A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combination therapy has not yet been reported. CASE PRESENTATION: A...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Adachi, Yuta, Yanagimura, Naohiro, Suzuki, Chiaki, Ootani, Sakiko, Tanimoto, Azusa, Nishiyama, Akihiro, Yamashita, Kaname, Ohtsubo, Koushiro, Takeuchi, Shinji, Yano, Seiji
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041078/
https://ncbi.nlm.nih.gov/pubmed/32093631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6626-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky